Pfizer’s blockbuster drug receives notice of approval!
January 30, 2026
Source: drugdu
34
According to the drug notification delivery information released by the NMPA (National Medical Products Administration) on January 27, 2026, Pfizer has received a notification regarding the supplemental New Drug Application (sNDA) for Talazoparib Tosylate Capsules. While the specific indication remains undisclosed, it is speculated to be for germline BRCA-mutated (gBRCAm) HER2-negative breast cancer.
Talazoparib Tosylate Capsules (brand name: TALZENNA®) is an inhibitor of poly (ADP-ribose) polymerase (PARP, including PARP1 and PARP2) enzymes, which play a role in DNA repair. In October 2024, the NMPA approved TALZENNA® in combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Initial Clinical Exploration of D-0502 in Combination with ADC Therapies Officially Commenced. January 30, 2026
- Aminophylline tablets pass generic drug consistency evaluation January 30, 2026
- Propafenone Hydrochloride Injection Receives Drug Production Registration Certificate January 30, 2026
- Hengrui’s innovative drug camrelizumab in combination with apatinib mesylate and TACE for the treatment of liver cancer has been accepted for marketing authorization application January 30, 2026
- The world’s first clinically approved “autologous regenerated islets” for the treatment of type 2 diabetes! Ruipuchen Chuang opens a new dual-indication autologous regeneration track. January 30, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
